Description: Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Home Page: www.alector.com
131 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
415 231 5660
Officers
| Name | Title |
|---|---|
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director |
| Dr. Saraswati Kenkare-Mitra Ph.D. | President and Head of Research & Development |
| Dr. Marc Grasso M.D. | CFO, Principal Financial Officer & Principal Accounting Officer |
| Dr. Gary Romano M.D., Ph.D. | Chief Medical Officer |
| Ms. Katie Hogan | Senior Director of Corporate Communication & Investor Relations |
| Ms. Danielle Pasqualone J.D., Ph.D. | General Counsel |
| Ms. Clare Hunt M.B.A. | Chief People Officer |
| Ms. Kristina Cutter M.P.H. | Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer |
| Ms. Virginia DeJesus-Rueff M.B.A. | Chief of Staff & Head of Strategy |
| Ms. Norah Conway | Senior Vice President of Portfolio & Program Management |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Energy |
|---|---|
| GIC Group: | Energy |
| GIC Industry: | Oil, Gas & Consumable Fuels |
| GIC Sub-Industry: | Coal & Consumable Fuels |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 2.3584 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 241 |